RxDoctor Payments Data

Ramon Ramirez, MD

Infectious Disease · Tamarac, FLNPI 1396844478

Payments from drug & device makers

$3,531in general payments, 2019–2025

Across 97 payments — averaging $36.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$989
  • Janssen Products, LP$886
  • AbbVie$424
  • Insmed, Inc.$358
  • Johnson & Johnson$321
  • Merck$174
  • plus $379 from 7 others

What the payments were for

  • Consulting fees$1003%
  • Food & beverage$3,28193%
  • Education$1504%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,531 in reported general payments places this provider in the 70th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$23,269
Medicare patients
59
Services billed
231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf171$840,436
BiktarvyBictegrav/Emtricit/Tenofov Ala80$315,966
JulucaDolutegravir/Rilpivirine65$223,315
GenvoyaElviteg/Cob/Emtri/Tenof Alafen25$110,390
PrezcobixDarunavir/Cobicistat16$41,890
TriumeqAbacavir/Dolutegravir/Lamivudi11$40,562
DovatoDolutegravir Sodium/Lamivudine12$38,341
CefuroximeCefuroxime Axetil14$177
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$123
Ciprofloxacin Hcl14$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Janssen Products, LPSymtuza$886$840,436171 claims
GileadBiktarvy, Genvoya$111$426,356105 claims
Viiv Healthcare CompanyJuluca, Triumeq, Dovato$989$302,21888 claims
Johnson & JohnsonPrezcobix$321$41,89016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →